viewSUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals encouraged by pharmacokinetic results evaluating anagrelide mouth spray

The company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals.

SUDA Pharmaceuticals Ltd - Suda Pharmaceuticals receives pharmacokinetic results evaluating novel mouth spray
SUDA Pharmaceuticals is a drug delivery company focused on oro-mucosal administration

SUDA Pharmaceuticals Ltd (ASX:SUD) is encouraged by preliminary results received from a pharmacokinetic study evaluating novel mouth spray formulations of anagrelide.

The study, which involved comparing three different mouth spray formulations against the current commercial capsule in a canine model, has been conducted by leading contract research organisation, Covance Inc, based in Harrogate, England.

Preliminary results from the crossover study using five animals suggest that one of the formulations was able to increase the bioavailability of anagrelide while reducing exposure to a cardio stimulatory metabolite.

Hypothesis supported

This supports SUDA’s hypothesis that such a formulation could be more safely administered to cancer patients, potentially resulting in fewer cardiovascular side-effects.

Suda will update the market with the results when the report has been finalised.

Working with “world-class people and research organisations”

Chief executive officer Dr Michael Baker said: “This is an exciting time for SUDA as we continue to advance this important project.

“There is still work to be done but we are making progress by working with world-class people and world-leading contract research organisations.”

The company will continue optimising the formulation to meet the requirements for a pharmaceutical-grade oral spray product before completing further preclinical testing.

Shares are up almost 7% to 4.6 cents.

SUDA Pharmaceuticals, which is headquartered in Perth, is a drug delivery company focused on oro-mucosal administration and is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals.

The many potential benefits of administering drugs through the oral mucosa (ie cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time.

Quick facts: SUDA Pharmaceuticals Ltd

Price: 0.034 AUD

Market: ASX
Market Cap: $5.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SUDA Pharmaceuticals Ltd named herein, including the promotion by the Company of SUDA Pharmaceuticals Ltd in any Content on the Site, the...



Musgrave Minerals Ltd's Rob Waugh delighted after hitting 85 metres at 11.6...

Musgrave Minerals Ltd's (ASX:MGV) (FRA:6MU) Rob Waugh says drilling at the new Starlight discovery is going 'very well' following news they've hit 85 metres at 11.6 g/t. ''It's close to surface, the mineralisation is starting at about six vertical metres down''. ''It's exciting, we're...

23 hours, 41 minutes ago

2 min read